Financing ·
Raises $6M in public offering of common units and warrants
SBFMSunshine Biopharma Inc.
Sunshine Biopharma Inc. closed a best-efforts public offering on October 9, 2026, raising approximately $6 million in gross proceeds. The company sold 10,509,082 common units at $0.55 per unit and 400,000 pre-funded units at $0.54999 per unit. Each unit includes two Series D warrants exercisable at $0.66 per share, which could generate an additional $14.4 million if fully exercised. Net proceeds will be used for general corporate purposes and working capital. Aegis Capital Corp. acted as the exclusive placement agent.